Chromocell appoints Frank Knuettel as permanent CEO, removing interim status

Pelthos Therapeutics Inc.

Frank Knuettel appointed permanent CEO effective March 13, 2024; previously interim CEO since July 2023.
Knuettel will continue as CFO, Treasurer, and Secretary of the company.
He has raised over $300M in capital and managed 15+ M&A transactions during his career.
Knuettel retains same compensation terms under existing amended consultant agreement.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Francis Knuettel II

Chief Executive Officer

PTHS · Pelthos Therapeutics Inc.

Effective: 2024-03-13
Filed: March 18, 2024, 7:59 PM ET

The board of directors (the “Board”) of Chromocell Therapeutics Corporation (the “Company”) has appointed Francis Knuettel II as Chief Executive Officer of the Company, effective March 13, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Francis Knuettel II was appointed as Chief Executive Officer at Pelthos Therapeutics Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

The board of directors (the “Board”) of Chromocell Therapeutics Corporation (the “Company”) has appointed Francis Knuettel II as Chief Executive Officer of the Company, effective March 13, 2024.

View on SEC.gov

Pelthos Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001753926-24-000550

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.